Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
151 studies found for:    Open Studies | "Thyroid Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting A Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Condition: Thyroid Cancer
Interventions: Drug: Lenvatinib;   Drug: Lenvatinib matching placebo
22 Recruiting Study of Apatinib in Patients With Differentiated Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Drug: Apatinib
23 Recruiting I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer
Condition: Differentiated Thyroid Carcinoma
Interventions: Radiation: Radioiodine I-131;   Radiation: I-124
24 Recruiting Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study
Condition: Thyroid Cancer
Intervention: Drug: gemcitabine -oxaliplatine combination
25 Recruiting Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer Patients
Condition: Thyroid Cancer
Intervention: Radiation: 99mTc sestamibi
26 Recruiting UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Condition: Thyroid Cancer
Interventions: Drug: Lenvatinib;   Drug: Everolimus
27 Recruiting Nintedanib(BIBF1120) in Thyroid Cancer
Conditions: Medullary Thyroid Cancer (MTC);   Differentiated Thyroid Cancer (DTC)
Interventions: Drug: Nintedanib;   Drug: Placebo
28 Recruiting A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Condition: Thyroid Cancer, Anaplastic
Intervention: Drug: Lenvatinib 24 mg
29 Recruiting Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
Condition: Thyroid Cancer
Intervention: Other: follow up visit
30 Not yet recruiting Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Condition: Differentiated Thyroid Cancer
Interventions: Drug: Donafenib 200mg;   Drug: Donafenib 300mg
31 Recruiting Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
Condition: Non-Medullary Thyroid Cancer
Intervention:
32 Recruiting A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
Condition: Differentiated Thyroid Cancer (DTC)
Interventions: Drug: Lenvatinib;   Drug: Placebo
33 Recruiting Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
Condition: Medullary Thyroid Cancer
Intervention: Other: 18F-DOPA
34 Not yet recruiting Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
Condition: Metastatic Thyroid Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Sirolimus
35 Recruiting Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
Condition: Differentiated Thyroid Cancer
Interventions: Drug: Anlotinib;   Drug: Placebo
36 Recruiting CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Conditions: Thyroid Neoplasms;   Poorly Differentiated and Undifferentiated Thyroid Cancer;   Differentiated Thyroid Cancer
Intervention: Drug: CUDC-907
37 Recruiting Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Condition: Thyroid Carcinoma
Interventions: Drug: Continuous pazopanib (Arm A);   Drug: Intermittent pazopanib (Arm B)
38 Recruiting Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Condition: Thyroid Carcinoma
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
39 Recruiting interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Condition: Anaplastic Thyroid Cancer
Intervention: Other: Tissue, blood and clinical data collection
40 Recruiting Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Condition: Low Risk Differentiated Thyroid Cancer
Interventions: Drug: rhTSH stimulation;   Drug: I131;   Other: Follow up

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.